These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 19370574)

  • 21. Methadone at tapered doses for the management of opioid withdrawal.
    Amato L; Davoli M; Ferri M; Ali R
    Cochrane Database Syst Rev; 2003; (2):CD003409. PubMed ID: 12804464
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Methadone at tapered doses for the management of opioid withdrawal.
    Amato L; Davoli M; Minozzi S; Ferroni E; Ali R; Ferri M
    Cochrane Database Syst Rev; 2013 Feb; 2013(2):CD003409. PubMed ID: 23450540
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lofexidine, an {alpha}2-receptor agonist for opioid detoxification.
    Gish EC; Miller JL; Honey BL; Johnson PN
    Ann Pharmacother; 2010 Feb; 44(2):343-51. PubMed ID: 20040696
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Buprenorphine for the management of opioid withdrawal.
    Gowing L; Ali R; White J
    Cochrane Database Syst Rev; 2000; (3):CD002025. PubMed ID: 10908521
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacological therapies for management of opium withdrawal.
    Rahimi-Movaghar A; Gholami J; Amato L; Hoseinie L; Yousefi-Nooraie R; Amin-Esmaeili M
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD007522. PubMed ID: 29929212
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Methadone at tapered doses for the management of opioid withdrawal.
    Amato L; Davoli M; Ferri M; Ali R
    Cochrane Database Syst Rev; 2002; (1):CD003409. PubMed ID: 11869660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Buprenorphine for the management of opioid withdrawal.
    Gowing L; Ali R; White J
    Cochrane Database Syst Rev; 2002; (2):CD002025. PubMed ID: 12076434
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal.
    Gowing L; Ali R; White JM
    Cochrane Database Syst Rev; 2010 Jan; 2010(1):CD002022. PubMed ID: 20091529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal.
    Gowing L; Ali R; White J
    Cochrane Database Syst Rev; 2006 Apr; (2):CD002022. PubMed ID: 16625552
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the effects of lofexidine and clonidine on naloxone-precipitated withdrawal in opioid-dependent humans.
    Walsh SL; Strain EC; Bigelow GE
    Addiction; 2003 Apr; 98(4):427-39. PubMed ID: 12653813
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of methadone, buprenorphine and alpha(2) adrenergic agonists for opioid detoxification: a mixed treatment comparison meta-analysis.
    Meader N
    Drug Alcohol Depend; 2010 Apr; 108(1-2):110-4. PubMed ID: 20074867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lofexidine for opiate detoxification: review of recent randomised and open controlled trials.
    Strang J; Bearn J; Gossop M
    Am J Addict; 1999; 8(4):337-48. PubMed ID: 10598217
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.
    Yu E; Miotto K; Akerele E; Montgomery A; Elkashef A; Walsh R; Montoya I; Fischman MW; Collins J; McSherry F; Boardman K; Davies DK; O'Brien CP; Ling W; Kleber H; Herman BH
    Drug Alcohol Depend; 2008 Sep; 97(1-2):158-68. PubMed ID: 18508207
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lofexidine versus clonidine for mitigation of opioid withdrawal symptoms: A systematic review.
    Kuszmaul AK; Palmer EC; Frederick EK
    J Am Pharm Assoc (2003); 2020; 60(1):145-152. PubMed ID: 31791720
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of clonidine, guanfacine and methadone in the rapid detoxification of heroin addicts: a controlled clinical trial.
    San L; Camí J; Peri JM; Mata R; Porta M
    Br J Addict; 1990 Jan; 85(1):141-7. PubMed ID: 1968773
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lofexidine versus diazepam for the treatment of opioid withdrawal syndrome: A double-blind randomized clinical trial in Singapore.
    Guo S; Manning V; Yang Y; Koh PK; Chan E; de Souza NN; Assam PN; Sultana R; Wijesinghe R; Pangjaya J; Kandasami G; Cheok C; Lee KM; Wong KE
    J Subst Abuse Treat; 2018 Aug; 91():1-11. PubMed ID: 29910009
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase III, randomized, multi-center, double blind, placebo controlled study of safety and efficacy of lofexidine for relief of symptoms in individuals undergoing inpatient opioid withdrawal.
    Gorodetzky CW; Walsh SL; Martin PR; Saxon AJ; Gullo KL; Biswas K
    Drug Alcohol Depend; 2017 Jul; 176():79-88. PubMed ID: 28527421
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alpha2-receptor agonists for treatment and prevention of iatrogenic opioid abstinence syndrome in critically ill patients.
    Honey BL; Benefield RJ; Miller JL; Johnson PN
    Ann Pharmacother; 2009 Sep; 43(9):1506-11. PubMed ID: 19690220
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.
    Mattick RP; Breen C; Kimber J; Davoli M
    Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD002207. PubMed ID: 24500948
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In-patient detoxification procedures, treatment retention, and post-treatment opiate use: comparison of lofexidine + naloxone, lofexidine + placebo, and methadone.
    McCambridge J; Gossop M; Beswick T; Best D; Bearn J; Rees S; Strang J
    Drug Alcohol Depend; 2007 Apr; 88(1):91-5. PubMed ID: 17064857
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.